BRINZOLAMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Brinzolamide, and when can generic versions of Brinzolamide launch?
Brinzolamide is a drug marketed by Bausch And Lomb, Padagis Us, and Watson Labs Inc. and is included in three NDAs.
The generic ingredient in BRINZOLAMIDE is brinzolamide. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the brinzolamide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Brinzolamide
A generic version of BRINZOLAMIDE was approved as brinzolamide by WATSON LABS INC on November 27th, 2020.
Summary for BRINZOLAMIDE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 96 |
| Clinical Trials: | 54 |
| Patent Applications: | 2,069 |
| Drug Prices: | Drug price information for BRINZOLAMIDE |
| What excipients (inactive ingredients) are in BRINZOLAMIDE? | BRINZOLAMIDE excipients list |
| DailyMed Link: | BRINZOLAMIDE at DailyMed |
Recent Clinical Trials for BRINZOLAMIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sun Pharmaceutical Industries Limited | Phase 3 |
| Peking University | N/A |
| General Hospital of Athens Elpis | N/A |
Pharmacology for BRINZOLAMIDE
| Drug Class | Carbonic Anhydrase Inhibitor |
| Mechanism of Action | Carbonic Anhydrase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for BRINZOLAMIDE
US Patents and Regulatory Information for BRINZOLAMIDE
BRINZOLAMIDE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting BRINZOLAMIDE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | BRINZOLAMIDE | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 204884-001 | Aug 18, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Padagis Us | BRINZOLAMIDE | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 211914-001 | Jul 28, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Watson Labs Inc | BRINZOLAMIDE | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 209406-001 | Nov 27, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for BRINZOLAMIDE
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Azopt | brinzolamide | EMEA/H/C/000267 Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. |
Authorised | no | no | no | 2000-03-09 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
